Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Resistentia Pharmaceuticals
company
About
Resistentia Pharmaceuticals develops immunotherapeutic products for allergic asthma and inflammatory disorders.
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $13.96M
- Industries
- Biotechnology,Health Care,Medical Device,Therapeutics
- Founded date
- Jan 1, 1998
- Operating Status
- Active
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$13.96M
Resistentia Pharmaceuticals has raised a total of
$13.96M
in funding over 2 rounds. Their latest funding was raised on
Sep 26, 2006 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 26, 2006 | Series C | $13.96M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Resistentia Pharmaceuticals is funded by 1 investors.
BankInvest Biomedical Venture
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
BankInvest Biomedical Venture
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
